Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment

Cancer

Volumn 104, Issue 3, 2005, Pages 532-540

  Nakamura, Shotaro ^a   Matsumoto, Takayuki ^a   Suekane, Hiroshi ^b   Nakamura, Shigeo ^a   Matsumoto, Hiroshi ^c   Esaki, Motohiro ^a   Yao, Takashi ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b YAMAGUCHI RED CROSS HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Chemotherapy; Gastric lymphoma; Helicobacter pylori; Mucosa associated lymphoid tissue; Radiotherapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; GASTRECTOMY; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INFECTION CONTROL; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STOMACH MUCOSA; THERAPY; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 22544467450     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21152     Document Type: Article

References (38)

1. Isaacson PG, Norton AJ. Extranodal lymphomas. Edinburgh: Churchill Livingstone, 1994.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lion: IARC Press, 2001.
3. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-1271.
4. Nakamura S, Yao T, Aoyagi K, et al. Helicobacter pylori and primary gastric lymphoma: a histopathologic and immunohisotochemical analysis of 237 patients. Cancer. 1997;79:3-11.
5. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575-577.
6. Bayerdörffer E, Neubarer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995;345:1591-1594.
7. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995;122:767-769.
8. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350-1355.
9. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999;131:88-95.
10. Savio A, Zamboni G, Capelli P, et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Recent results. Cancer Res. 2000;156:116-124.
11. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001;48:297-303.
12. Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut. 2001;48:454-460.
13. Liu H, Ye H, Ruskoné-Fourmestraux A, et al. T(11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286-1294.
14. Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter pylori and gastric MALT lymphoma. Gut. 2002;50(Suppl 3): iii19-iii24.
15. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53:34-37.
16. Cogliatti SB, Schimid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101:1159-1170.
17. Nakamura S, Akazawa K, Yao T, et al. Primary gastric lymphoma: a clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer. 1995;76:1313-1324.
18. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology. 2000;119:1191-1202.
19. Blazquez M, Haioun C, Chaumette MT, et al. Low grade B cell mucosa associated lymphoid tissue lymphoma of the stomach: clinical and endoscopic features, treatment, and outcome. Gut. 1992;33:1621-1625.
20. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13:2524-2529.
21. Taal BG, Boot H, van Heerde P, et al. Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut. 1996;39:556-561.
22. Schechter NR, Partlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916-1921.
23. Willich NA, Reinartz G, Horst EJ, et al. Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study. Int J Radiat Oncol Biol Phys. 2000;46:895-901.
24. 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology. 2003;227:353-360.
25. Rohatiner A, d'Amore F, Coiffler B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397-400.
26. Nakamura S, Matsumoto T, Nakamura S, et al. Chromosomal translocation t(11; 18) (q21; q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol. 2003;56:36-42.
27. Nakamura S, Aoyagi K, Furuse M, et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. Am J Pathol. 1998;152:1271-1279.
28. Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-2745.
29. Wöhrer S, Püspök A, Drach J, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004;15:1086-1090.
30. Matsumoto H, Koga H, Iida M, et al. Helicobacter-independent, chemotherapy-resistant, radiosensitive gastric MALT lymphoma with massive deposits of amyloidlike substance. Dig Dis Sci. 2003;48:2018-2022.
31. Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol. 2001;19:2041-2048.
32. E high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245-4251.
33. Nakamura T, Nakamura S, Yonezumi M, et al. Helicobacter pylori and the t(11; 18) (q21; q21) translocation in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J Cancer Res. 2000;91:301-309.
34. Isaacson PG, Diss TC, Wotherspoon AC, et al. Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibiotics. Gastroenterology. 1999;117:750-751.
35. Montalbàn C, Castrillo JM, López-Abente G, et al. Other cancers in patients with gastric MALT lymphoma. Leuk Lymphoma. 1999;33:161-168.
36. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
37. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British Cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498-509.
38. Baron BW, Bitter MA, Baron JM, et al. Gastric adenocarcinoma after gastric lymphoma. Cancer. 1987;60:1876-1882.